76 related articles for article (PubMed ID: 21989766)
1. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
Chow LQ; Blais N; Jonker DJ; Laurie SA; Diab SG; Canil C; McWilliam M; Thall A; Ruiz-Garcia A; Zhang K; Tye L; Chao RC; Camidge DR
Cancer Chemother Pharmacol; 2012 Mar; 69(3):709-22. PubMed ID: 21989766
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
Michaelson MD; Zhu AX; Ryan DP; McDermott DF; Shapiro GI; Tye L; Chen I; Stephenson P; Patyna S; Ruiz-Garcia A; Schwarzberg AB
Br J Cancer; 2013 Apr; 108(7):1393-401. PubMed ID: 23511559
[TBL] [Abstract][Full Text] [Related]
3. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.
Heist RS; Wang X; Hodgson L; Otterson GA; Stinchcombe TE; Gandhi L; Villalona-Calero MA; Watson P; Vokes EE; Socinski MA;
J Thorac Oncol; 2014 Feb; 9(2):214-21. PubMed ID: 24419419
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
Rini B; Redman B; Garcia JA; Burris HA; Li S; Fandi A; Beck R; Jungnelius U; Infante JR
Ann Oncol; 2014 Sep; 25(9):1794-1799. PubMed ID: 24914044
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer.
Novello S; Scagliotti GV; Rosell R; Socinski MA; Brahmer J; Atkins J; Pallares C; Burgess R; Tye L; Selaru P; Wang E; Chao R; Govindan R
Br J Cancer; 2009 Nov; 101(9):1543-8. PubMed ID: 19826424
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
Davies JM; Dhruva NS; Walko CM; Socinski MA; Bernard S; Hayes DN; Kim WY; Ivanova A; Keller K; Hilbun LR; Chiu M; Dees EC; Stinchcombe TE
Lung Cancer; 2011 Feb; 71(2):151-5. PubMed ID: 20580118
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.
O'Mahar SE; Campbell TC; Hoang T; Seo S; Kim K; Larson MM; Marcotte SM; LoConte NK; Traynor AM
J Thorac Oncol; 2011 May; 6(5):951-3. PubMed ID: 21623267
[TBL] [Abstract][Full Text] [Related]
8. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Socinski MA; Novello S; Brahmer JR; Rosell R; Sanchez JM; Belani CP; Govindan R; Atkins JN; Gillenwater HH; Pallares C; Tye L; Selaru P; Chao RC; Scagliotti GV
J Clin Oncol; 2008 Feb; 26(4):650-6. PubMed ID: 18235126
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.
Argiris A; Karamouzis MV; Smith R; Kotsakis A; Gibson MK; Lai SY; Kim S; Branstetter BF; Shuai Y; Romkes M; Wang L; Grandis JR; Ferris RL; Johnson JT; Heron DE
Ann Oncol; 2011 Nov; 22(11):2482-2488. PubMed ID: 21363880
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Reardon DA; Vredenburgh JJ; Coan A; Desjardins A; Peters KB; Gururangan S; Sathornsumetee S; Rich JN; Herndon JE; Friedman HS
J Neurooncol; 2011 Dec; 105(3):621-7. PubMed ID: 21744079
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.
Schelman WR; Morgan-Meadows S; Marnocha R; Lee F; Eickhoff J; Huang W; Pomplun M; Jiang Z; Alberti D; Kolesar JM; Ivy P; Wilding G; Traynor AM
Cancer Chemother Pharmacol; 2009 May; 63(6):1147-56. PubMed ID: 19082825
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.
Azad N; Perroy A; Gardner E; Imamura CK; Graves C; Sarosy GA; Minasian L; Kotz H; Raggio M; Figg WD; Kohn EC
Cancer Biol Ther; 2009 Oct; 8(19):1800-5. PubMed ID: 19738417
[TBL] [Abstract][Full Text] [Related]
13. Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma.
Kesari S; Wagle N; Carrillo JA; Sharma A; Nguyen M; Truong J; Gill JM; Nersesian R; Nomura N; Rahbarlayegh E; Barkhoudarian G; Sivakumar W; Kelly DF; Krauss H; Bustos MA; Hoon DSB; Anker L; Singh AS; Sankhala KK; Juarez TM
Clin Cancer Res; 2024 Jan; 30(2):323-333. PubMed ID: 38047868
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Kristeleit R; Plummer R; Jones R; Carter L; Blagden S; Sarker D; Arkenau T; Evans TRJ; Danson S; Symeonides SN; Veal GJ; Klencke BJ; Kowalski MM; Banerji U
Br J Cancer; 2023 Jul; 129(1):38-45. PubMed ID: 37120671
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study.
Koldenhof JJ; Lankheet NAG; Steeghs N; Teunissen SCCM; Witteveen PO
Support Care Cancer; 2018 Aug; 26(8):2641-2650. PubMed ID: 29464389
[TBL] [Abstract][Full Text] [Related]
16. Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development.
Lu Y; Liang S; Hong Y; Tajima N; Patel K; Li H; Wada DR; Greenberg J; Petrich A; Zebger-Gong H; Shuster D; Vaddady P
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):23-28. PubMed ID: 37915242
[TBL] [Abstract][Full Text] [Related]
17. A Phase I Trial of the MET/
Piha-Paul SA; Dumbrava EE; Nair BC; Xiong W; Xu L; Mostorino R; Subbiah V; Tannir N; Fu S; Naing A; Janku F; Karp DD; Patel S; Daw NC; Hong D; Meric-Bernstam F; Zinner R
Onco Targets Ther; 2021; 14():3037-3049. PubMed ID: 33994796
[TBL] [Abstract][Full Text] [Related]
18. [Progress of platelet derived grow factor family in non-small cell lung cancer].
Tian Y; Chu Q; Chen Y
Zhongguo Fei Ai Za Zhi; 2014 Jan; 17(1):42-8. PubMed ID: 24398313
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
Blais N; Camidge DR; Jonker DJ; Soulières D; Laurie SA; Diab SG; Ruiz-Garcia A; Thall A; Zhang K; Chao RC; Chow LQ
Invest New Drugs; 2013 Dec; 31(6):1487-98. PubMed ID: 23963796
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
